Viking Therapeutics Earnings Hinge on Whether Pipeline Progress Can Offset Another Quarter Without Revenue

Viking Therapeutics (VKTX) reports second-quarter 2026 earnings on July 22, 2026, with analysts expecting a loss of $1.21 per share—more than double the $0.58 loss reported in the same quarter last year. The central question is whether the biotech can demonstrate progress on its pipeline programs while managing escalating development costs, as the company navigates a critical phase with multiple clinical catalysts on the horizon.

Part 1: Earnings Preview

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with lead programs targeting obesity, NASH (non-alcoholic steatohepatitis), and other metabolic diseases. The company's pipeline has attracted significant investor attention as it advances multiple candidates through clinical trials.

For the quarter ended June 2026, analysts expect Viking to report a loss of $1.21 per share on July 22nd. The company most recently reported a loss of $1.37 per share for the first quarter of 2026. Compared to the $0.58 loss reported in the second quarter of 2025, the consensus estimate represents a 108.62% deterioration year-over-year, reflecting increased R&D spending as clinical programs advance.

Three key themes define this earnings story:

Clinical Pipeline Progress: Investors will scrutinize updates on Viking's obesity and NASH programs, particularly any data readouts or enrollment milestones that could validate the company's therapeutic approach and differentiate it from competitors in the crowded metabolic disease space.

Cash Runway and Funding Strategy: With losses widening significantly, the company's cash position and burn rate will be critical. Analysts will assess whether Viking has sufficient capital to reach key clinical milestones or if additional financing will be needed, which could dilute existing shareholders.

Competitive Positioning: As multiple biotechs race to develop next-generation obesity and metabolic disease treatments, Viking's ability to demonstrate differentiated efficacy, safety, or convenience profiles will be essential to maintaining its premium valuation and analyst support.

Analyst commentary ahead of the release remains cautiously optimistic, with the Street focused on clinical execution rather than near-term profitability. The consensus acknowledges that widening losses are expected as the company invests heavily in advancing its pipeline, but any signs of clinical setbacks or delays could trigger significant downside given the stock's elevated valuation relative to its development stage.

Part 2: Historical Earnings Performance

Viking Therapeutics has consistently missed earnings estimates over the past four quarters, with surprises ranging from -15.71% to -55.06%. The most recent quarter (Q1 2026) saw the company report a loss of $1.37 per share versus the $0.95 consensus, representing a -44.21% miss. The prior quarter (Q4 2025) delivered the largest disappointment, with a $1.38 loss against a $0.89 estimate for a -55.06% shortfall.

The pattern reveals a clear trend of deteriorating performance relative to expectations. Reported losses have escalated from $0.58 in Q2 2025 to $1.37 in Q1 2026, more than doubling in just three quarters. Simultaneously, the company has consistently underperformed analyst estimates by widening margins, suggesting either overly optimistic Street projections or accelerating cost pressures that have outpaced forecasts. This track record of negative surprises raises the bar for the upcoming release, as investors will be particularly sensitive to any further deterioration beyond the already elevated $1.21 consensus estimate.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Viking Therapeutics typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Viking's post-earnings price behavior has been highly volatile and directionally mixed. On the day of earnings (Day 0), the stock has averaged an absolute move of 2.79% with an average range of 5.14%, indicating moderate intraday volatility. However, Day +1 reactions have been far more dramatic, with an average absolute move of 8.96% and an average range of 13.39%, suggesting the market often takes time to fully digest results and implications.

The most notable pattern is the extreme upside reactions following certain releases: the October 2024 and July 2024 reports both triggered Day +1 surges exceeding 21% and 28% respectively, likely driven by positive clinical updates or pipeline developments that overshadowed the headline EPS misses. Conversely, more recent quarters have shown muted reactions, with the April 2026 report producing only a -3.27% Day 0 move and minimal follow-through. This suggests investors have become more discerning, focusing on operational execution and clinical milestones rather than reacting purely to earnings beats or misses. Given the current 2.58% expected move implied by options, the market is pricing in a relatively subdued reaction compared to the 8.96% historical Day +1 average, potentially underestimating volatility risk if the company delivers meaningful pipeline updates.

Part 2.2: Options Market Expected Move

The options market is pricing in a 2.58% expected move through July 24th expiration, significantly below the stock's 8.96% average Day +1 move following past earnings releases. This suggests options traders may be underpricing potential volatility, particularly given Viking's history of delivering double-digit percentage swings when clinical updates accompany financial results.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Viking Therapeutics, with the consensus rating at 4.70 out of 5.00—firmly in Strong Buy territory. The current breakdown shows 17 Strong Buys, 0 Moderate Buys, 3 Holds, and 0 Sells, reflecting overwhelming optimism about the company's long-term prospects despite near-term losses.

The average price target of $89.00 implies 134% upside from the current price of $37.95, with estimates ranging from a low of $34.00 (roughly in line with current levels) to a high of $125.00 (suggesting potential for more than tripling). This wide range reflects differing views on the probability and timeline for clinical success, but the concentration of Strong Buy ratings indicates most analysts believe the risk-reward profile favors the bulls.

Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.70. This stability suggests analysts are maintaining conviction in their bullish thesis despite the stock's recent consolidation and the pattern of earnings misses. The lack of downgrades following consecutive disappointing quarters indicates the Street is willing to look through near-term financial performance and focus on pipeline progress as the primary value driver.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 48% Buy signal, representing a notable improvement from the 40% Buy reading last week and a dramatic reversal from the 88% Sell signal just one month ago. This rapid shift from bearish to neutral-bullish territory suggests momentum has stabilized after a period of weakness, though the signal remains below a strong conviction level.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive signal indicates near-term momentum has recovered from recent lows but lacks strong directional conviction
• Medium-term (25% Buy): Weak buy signal suggests the intermediate trend remains tentative with limited follow-through
• Long-term (50% Buy): Neutral reading reflects a balanced longer-term technical picture without clear trend dominance

Trend Characteristics: The signal strength is rated as Average and the direction is Strengthening, indicating the technical environment is gradually improving but has not yet established a robust uptrend heading into earnings.

The stock is currently trading at $37.95, positioned above its 5-day moving average of $37.12 but below both its 10-day ($38.16) and 20-day ($38.18) moving averages, suggesting recent consolidation near resistance. However, the price remains above all longer-term moving averages—the 50-day ($33.42), 100-day ($33.42), and 200-day ($33.71)—confirming the broader uptrend remains intact despite short-term choppiness.

Key resistance sits at the $38.16-$38.18 zone where the 10-day and 20-day moving averages converge, while support is established at the $33.42 level marked by both the 50-day and 100-day moving averages. The technical setup is cautiously supportive heading into earnings: the stock has held above major support levels and is showing signs of stabilization, but it needs to reclaim the $38 area to confirm renewed momentum. The improving Barchart Opinion signal and strengthening trend direction suggest the path of least resistance may be higher if the company delivers on clinical expectations, though the proximity to short-term resistance means a disappointing report could trigger a test of the $33-$34 support zone.